 Home > Active Ingredient News > Antitumor Therapy > J Immunother Cancer: Types of drug resistance and imaging changes during anti-PD-1 immunotherapy for advanced melanoma

J Immunother Cancer: Types of drug resistance and imaging changes during anti-PD-1 immunotherapy for advanced melanoma

 Last Update: 2021-03-20
 Source: Internet
 Author: User

Tags

mirror image definition

vortex 1 10

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Anti-programmed cell death protein 1 (PD-1) monotherapy has greatly changed the prospect of systemic treatment of advanced melanoma, but drug resistance hinders the clinical application of anti-PD-1 antibodies.

immunity

In this study, independent radiologists performed single-blind radiation on 254 patients with advanced melanoma (median follow-up 31 months) who received anti-PD-1 monotherapy at Massachusetts General Hospital and Peking University Cancer Hospital.

The most significant changes in the target lesion examination occurred within the first 3 months after anti-PD-1 treatment.

In multivariate analysis, patients with deeper remission will have less disease progression, fewer organs involved, lighter tumor burden, slower growth rate during tumor progression (PD) (all p≤0.

Compared with primary drug resistance, secondary drug resistance is associated with less PD distribution, lower tumor burden, and slower tumor growth (all p≤0.

Patients with secondary drug resistance are less likely to receive further systemic treatment (28% vs 57%, p<0.

The imaging findings are variable and significantly correlated with survival results.

Original source:

Bai Xue,Kim Michelle,Kasumova Gyulnara et al.

bmj.
com/content/9/2/e002092" target="_blank" rel="noopener">Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.